Wells Fargo & Company Cti Biopharma Corp Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$4.2 - $6.01 $870,534 - $1.25 Million	207,270 New	207,270 $870,000
Q3 2022 Nov 14, 2022	BUY	$5.36 - $7.43 $8,442 - $11,702	1,575 Added 26.92%	7,426 $43,000
Q2 2022 Aug 12, 2022	BUY	$3.55 - $6.27 $18,996 - $33,550	5,351 Added 1070.2%	5,851 $35,000
Q1 2022 May 16, 2022	SELL	$1.9 - $5.23 $32 - $88	-17 Reduced 3.29%	500 $2,000
Q4 2021 Feb 14, 2022	BUY	$1.44 - $2.86 $1 - $2	1 Added 0.19%	517 $1,000
Q3 2021 Nov 15, 2021	SELL	$2.25 - $3.18 $60 - $85	-27 Reduced 4.97%	516 $2,000
Q2 2021 Aug 16, 2021	BUY	$2.16 - $2.62 $358 - $434	166 Added 44.03%	543 $1,000
Q1 2021 May 13, 2021	SELL	$2.68 - $3.8 $130,068 - $184,425	-48,533 Reduced 99.23%	377 $1,000
Q4 2020 Feb 09, 2021	BUY	$2.48 - $3.8 $120,433 - $184,535	48,562 Added 13954.6%	48,910 $157,000
Q3 2020 Nov 05, 2020	SELL	$1.02 - $2.15 $265 - $559	-260 Reduced 42.76%	348 $1,000
Q2 2020 Aug 13, 2020	BUY	$0.88 - $1.32 $139 - $208	158 Added 35.11%	608 $1,000
Q1 2020 May 14, 2020	BUY	$0.69 - $1.54 $310 - $693	450 New	450 $0

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.